Immunovant director granted RSUs and stock options
Immunovant, Inc. director Andrew J. Fromkin received equity compensation on April 7, 2026.
Rhea-AI Filing Summary
Immunovant, Inc. director Andrew J. Fromkin received equity compensation on April 7, 2026. He was granted 13,880 restricted stock units under the 2019 Equity Incentive Plan, with each RSU representing one share of common stock upon vesting.
He was also granted stock options for 7,061 shares of common stock at an exercise price of $24.61 per share, expiring April 7, 2036. Both the RSUs and options vest in full on April 1, 2027, subject to his continuous service. Following the RSU grant, he holds 99,732 shares of common stock directly, and the RSUs may be settled later if he elects deferral under Rule 409A.
Positive
- None.
Negative
- None.
Insider Trade Summary
Grant/Award: 20,941 shares
Grant/Award
2 txns
Insider
Fromkin Andrew J.
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 7,061 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 13,880 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (right to buy) — 7,061 contracts (Direct);
Common Stock — 99,732 shares (Direct)
Footnotes (2)
- F1. These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date. The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A.
- F2. These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027, subject to the Reporting Person's continuous service to the Issuer as of such date.
Key Figures
RSU grant size: 13,880 RSUs
Stock options granted: 7,061 options
Option exercise price: $24.61 per share
+3 more
6 metrics
RSU grant size
13,880 RSUs
Restricted stock units granted April 7, 2026, vesting April 1, 2027
Stock options granted
7,061 options
Options to buy common stock granted April 7, 2026
Option exercise price
$24.61 per share
Exercise price for 7,061 stock options
Option expiration date
April 7, 2036
Expiration of newly granted stock options
Common shares after grant
99,732 shares
Total direct common stock holdings following RSU grant
Vesting date
April 1, 2027
Full vesting date for both RSUs and options
Key Terms
restricted stock units ("RSUs"), 2019 Equity Incentive Plan, continuous service, Rule 409A, +1 more
5 terms
restricted stock units ("RSUs") financial
"These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan"
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
2019 Equity Incentive Plan financial
"These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan"
continuous service financial
"The RSUs will vest in full on April 1, 2027, subject to the Reporting Person's continuous service"
Rule 409A financial
"The Reporting Person may elect to defer settlement of the RSUs upon vesting, subject to the requirements of Rule 409A"
stock options financial
"These options were granted pursuant to the Plan. The shares underlying the options will vest on April 1, 2027"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What equity awards did Immunovant (IMVT) director Andrew Fromkin receive?
Andrew J. Fromkin received 13,880 restricted stock units and stock options for 7,061 shares of Immunovant common stock. Both awards were granted under the company’s 2019 Equity Incentive Plan as part of his director compensation package.
When do Andrew Fromkin’s newly granted Immunovant RSUs and options vest?
Both the 13,880 RSUs and the options for 7,061 shares will vest in full on April 1, 2027. Vesting is conditioned on Fromkin’s continuous service with Immunovant through that date under the terms of the 2019 Equity Incentive Plan.
What is the exercise price and term of Andrew Fromkin’s new Immunovant stock options?
The new stock options allow Andrew Fromkin to buy 7,061 Immunovant common shares at an exercise price of $24.61 per share. These options were granted on April 7, 2026 and are scheduled to expire on April 7, 2036, if not exercised earlier.
Can settlement of Andrew Fromkin’s Immunovant RSUs be deferred?
Yes. The RSUs granted to Andrew Fromkin may be deferred upon vesting if he elects deferral, subject to Rule 409A requirements. Each RSU represents a contingent right to receive one share of Immunovant common stock when ultimately settled.
Under what plan were Andrew Fromkin’s Immunovant RSUs and options granted?
Both the RSUs and stock options granted to Andrew Fromkin were issued under Immunovant’s 2019 Equity Incentive Plan. This plan governs the terms of his awards, including vesting on April 1, 2027, and the conditions related to continued service.
AI-generated analysis. How Rhea-AI works. Not financial advice.
